A clinical trial does not simply run until it’s done. Its regulatory status is a series of discrete IRB determinations: renewal (continuing review that keeps an open study’s approval active), closure (the formal determination that IRB oversight of the study has ended), and, less commonly, reopening (restoring active status to a study the IRB had already closed). Each is a distinct administrative act with its own triggers, documentation, and consequences for what study staff may and may not do. Confusing them — treating a lapsed renewal as if it were a closure, or assuming a closed study can simply resume without new IRB action — is a common source of protocol deviations and reportable noncompliance.
This guide covers all three determinations in sequence: how continuing review renews an open study’s approval, what happens when that renewal lapses, what a formal closure actually requires, and what reopening a closed study typically involves. It assumes familiarity with the underlying review mechanism — see the Continuing Review (IRB) entry for the operational definition if you need that grounding first.
Study Renewal: Continuing Review and Its Interval
For research that received full-board review, the IRB must periodically re-review it to decide whether approval should continue. This is continuing review, and it is the mechanism by which a study’s approval is “renewed.”
Under 45 CFR 46.109(e) (the Common Rule), continuing review must occur at intervals appropriate to the degree of risk, but not less than once per year. The 2018 Common Rule revisions added 46.109(f), which removes the continuing-review requirement entirely — not merely permits an expedited version of it — for three categories: research eligible for expedited review, research receiving limited IRB review under specific exemption categories, and research that has closed to enrollment and moved solely into data analysis or standard-of-care follow-up. Institutions that have adopted the revised Common Rule apply these exceptions; some legacy protocols and non-adopting institutions still require annual review regardless.
FDA-regulated research does not get the same relief. 21 CFR 56.109(f), FDA’s parallel provision, still requires continuing review of FDA-regulated research at intervals appropriate to risk, not less than annually, without the 2018 HHS exceptions. A drug or device trial reviewed under FDA regulations (see 21 CFR Part 56) generally cannot rely on the enrollment-closed or exemption-based carve-outs available under the Common Rule.
Because expedited review requires the research to be no more than minimal risk, a greater-than-minimal-risk study can never use an expedited continuing-review pathway at any interval — it must go before the convened board each renewal cycle, regardless of how routine the study has become.
When Continuing Review Lapses
A lapse occurs whenever the investigator fails to submit the continuing-review materials in time, or the IRB has not completed its re-review and reapproval before the current approval’s expiration date. Per OHRP’s 2010 Guidance on IRB Continuing Review of Research, the default consequence of a lapse is that all study activities involving human subjects must stop — no new enrollment, no further interventions or interactions with subjects — until the IRB completes continuing review and reapproves the research.
The one narrow exception OHRP’s guidance recognizes is that it may be permissible to continue an enrolled subject’s participation during a lapse if the IRB (or IRB chair, under delegated authority) determines it is in that subject’s best interests to do so — for example, continuing a medication a subject is already stable on rather than abruptly stopping study-related care. That determination is study- and subject-specific; it is not a blanket authorization to keep a study running informally until paperwork catches up. Institutions vary in how they operationalize this guidance in their own written policies, so the exact escalation and documentation steps depend on the local IRB’s SOPs, but the underlying default — approval expires, activity stops, resumption requires IRB action — is consistent across HHS- and FDA-regulated research.
Formal Study Closure
Closure is the IRB’s determination that its oversight of a study has ended — distinct from a lapse, which is an unintended interruption, and distinct from the 46.109(f) exemption from continuing review, which keeps the study formally open while relieving it of the annual review cycle. Closure is typically initiated by the study team submitting a final/closure report once the last subject has completed all study procedures (or, for FDA-regulated drug trials, once the sponsor withdraws the investigational new drug application).
A closure submission generally documents: final enrollment and completion figures; a summary of adverse events and any unanticipated problems reported during the study (see IRB Noncompliance and Unanticipated Problem Reporting); disposition of any investigational drug, device, or biologic; and confirmation of what happens to identifiable data and specimens going forward (continued use under the original consent, destruction, or transfer to a repository under separate authorization).
For IND drug studies, closure is tied to the sponsor’s obligations under 21 CFR 312.38: a sponsor may withdraw an IND at any time, at which point FDA must be notified, all investigations under that IND must end, all investigators notified, and unused drug supply returned to the sponsor or otherwise disposed of consistent with investigator recordkeeping obligations under 21 CFR 312.62. If the withdrawal is for a safety reason, the sponsor must promptly inform FDA, participating investigators, and all reviewing IRBs of the reasons.
Closure does not end record-retention obligations — it starts the clock on them. Under 21 CFR 312.62(c), investigator records for a drug study must be retained for two years following the date a marketing application is approved for the indication studied, or, if no application is approved, until two years after the investigation is discontinued and FDA is notified. Federally funded research carries a separate obligation: under 2 CFR 200.334, financial and supporting records tied to the award must be retained for three years from the date the final financial report is submitted, extended further if litigation, a claim, or an audit involving those records is open at the three-year mark. These two retention clocks run independently and on different triggers, so a closed study can have record-retention obligations under one, both, or neither depending on funding source and regulatory pathway — don’t assume a single retention date covers everything. See also Project closure documentation for the broader award-closeout record set.
Reopening a Closed Study
Reopening is the least standardized of the three determinations — no single federal regulation defines it, because closure itself is an institutional IRB action rather than a distinct regulatory status with its own reopening procedure written into the Common Rule or FDA regulations. What governs reopening in practice is the same underlying principle that governs closure and lapse: a study without current, active IRB approval may not involve human subjects in research activities, so restoring that status requires new IRB action, not an administrative reactivation.
Reasons a study team requests reopening vary: a need to re-contact prior participants for long-term follow-up not anticipated at closure, discovery that closure was submitted in error while procedures were still ongoing, a new funding period requiring additional data collection under the same protocol, or a sponsor deciding to resume an IND that was previously withdrawn. In each case, most IRBs treat the request less like flipping a switch and more like a fresh determination: the board (or a designated reviewer, depending on the scope of what’s being reopened) needs to assess whether the protocol and consent documents are still current relative to institutional policy and the regulatory landscape, whether the original risk/benefit determination still holds, and whether previously enrolled subjects would need to be reconsented under an updated form before any further study-related contact. Where the original approval period has long since lapsed, institutions commonly process a reopening request as equivalent to a new initial review rather than a simple reinstatement, precisely because the regulatory basis for treating it as a continuation — an unbroken chain of periodic reapproval — no longer exists once the study has been formally closed.
Because these procedures are set at the institutional level, the concrete steps (which form to submit, whether expedited reinstatement is available for minimal-risk studies, how long a “closed” record is kept queryable before it’s archived) differ across IRBs. Study teams anticipating a need to reopen a study — for example, ahead of a planned long-term follow-up phase — are generally better served by closing to enrollment while keeping the protocol open under the 46.109(f) reduced-review pathway (where applicable) than by fully closing and having to rebuild IRB approval from a new initial review later.
Renewal, Closure, and Reopening at a Glance
- Renewal (continuing review): keeps an open study’s approval active; interval risk-based, floor of one year under 45 CFR 46.109(e); FDA-regulated research has no exemption from this cycle under 21 CFR 56.109(f); the 2018 Common Rule’s 46.109(f) removes the requirement for expedited-eligible, limited-review, or enrollment-closed/analysis-only research under HHS jurisdiction.
- Lapse: an unintended gap when renewal isn’t completed by the expiration date; default is all subject-facing activity stops except where continuing an enrolled subject’s participation is determined to be in that subject’s best interest.
- Closure: a deliberate IRB determination that oversight has ended, documented via a final/closure report; starts record-retention clocks (21 CFR 312.62(c) for IND drug records; 2 CFR 200.334 for federally funded award records) rather than ending them.
- Reopening: restoring active status to a closed study; governed by institutional policy rather than a specific federal provision, and commonly processed as equivalent to a new initial review once the original approval chain has been broken.
Frequently Asked Questions
Does closing a study to new enrollment mean the study is closed?
No. Closing to enrollment is a status change within an open study — it can trigger the 46.109(f) exemption from continuing review once the study has moved to data-analysis-only or standard-of-care follow-up, but the study remains under IRB oversight until a formal closure determination is made and documented.
Can study activities continue during a continuing-review lapse?
Generally no. Per OHRP’s 2010 guidance, the default is that all subject-facing research activity stops until the IRB completes continuing review and reapproves the research, with the narrow exception of continuing an already-enrolled subject’s participation if the IRB determines that continuation is in that subject’s best interest.
How long must investigator records be kept after a drug study closes?
Under 21 CFR 312.62(c), at least two years following the date a marketing application is approved for the studied indication, or two years after the investigation is discontinued and FDA notified if no application is approved. Federally funded studies separately carry a three-year record-retention requirement from final financial report submission under 2 CFR 200.334, which can run longer or shorter than the FDA clock depending on timing.
Is reopening a closed study the same process as continuing review?
No. Continuing review renews an already-open study’s approval on schedule. Reopening restores IRB oversight to a study whose approval had already ended, and because that unbroken chain of periodic reapproval has been broken, most institutions treat it as equivalent to a new initial review rather than a simple reinstatement.
